Ipamorelin vs CJC-1295: Two Receptors, Two Evidence Files

Searches for ipamorelin vs CJC 1295 usually assume the two compounds are variations on a theme. They are not. They act on two different receptors, they were developed from two different starting molecules, and — the part that gets least attention — their published evidence files are not remotely comparable in depth. This is a receptor-level and literature-level review of both, including what the record does not contain.
The two receptors, stated plainly
| Ipamorelin | CJC-1295 (no DAC) | |
|---|---|---|
| Receptor target | Ghrelin receptor (GHS-R1a) | GHRH receptor (inferred, not measured directly) |
| Molecular class | Synthetic pentapeptide growth hormone secretagogue | Tetrasubstituted analog of GHRH(1–29) |
| Also known as | — | Modified GRF (1–29) |
| Origin | Developed at Novo Nordisk, described 1998 | Derived from the CJC-1295 series, with the albumin-binding complex removed |
| Human data | Pharmacokinetic study plus a completed phase 2 trial | No peer-reviewed human studies found |
| Evidence stage | Phase 2 tested; not approved | Preclinical / inferred |
Both receptors converge on the same pituitary cell type — the somatotroph — which is why the two compounds are routinely discussed together. Convergence downstream is not equivalence upstream, and the two literatures behave very differently.
Ipamorelin: a ghrelin-receptor agonist with an unusually clean selectivity story
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed at Novo Nordisk and described in 1998 as the first selective agent of its class (Raun et al., 1998). Five residues makes it one of the smaller molecules in this category, and small, fully synthetic sequences are the easiest to characterise analytically.
It acts on the ghrelin receptor, GHS-R1a, stimulating growth hormone release from the pituitary. The claim that earned it the “selective” label is a negative result rather than a positive one: in swine it did not raise ACTH or cortisol, unlike GHRP-2 and GHRP-6 (Raun et al., 1998). Two caveats belong with that finding. It is swine data, so the species boundary is real; and the original paper's own receptor language was cautious — it described a “GHRP-like receptor”, with the explicit GHS-R1a attribution coming from later literature, including a phase 2 report and a 2026 review of this compound class (Dominikowski et al., 2026).
Human pharmacokinetics — and what “half-life” means here
A pharmacokinetic–pharmacodynamic modelling study in healthy human volunteers (Gobburu et al., 1999) is the reason ipamorelin has a real human pharmacology file at all. The qualitative result that matters for interpretation: the study observed a single, short-lived growth hormone release episode. That is a statement about the shape of the response, not a recommendation about anything.
It is worth separating two distinct “half-life” concepts that the secretagogue literature mixes freely. The first is the clearance half-life of the peptide itself — how long the molecule persists. The second is the duration of the hormonal response it elicits, which is governed by pituitary store depletion and feedback rather than by the molecule's persistence. A short-lived, self-limiting release episode is consistent with a small peptide and a receptor system that does not sustain output indefinitely. Published numerical parameters belong to the modelling paper; this review does not restate figures it has not verified there.
The phase 2 result, which is the most informative part of the file
Ipamorelin was carried into a randomized, placebo-controlled phase 2 trial in bowel-resection patients, registered as NCT00672074 with 117 enrolled and sponsored by Helsinn Therapeutics. The published report (Beck et al., 2014) found it well tolerated but showed no significant difference from placebo on the recovery endpoints studied. There is no approval for it anywhere.
That is a clean, interpretable, negative controlled result — and it is more evidence than most compounds in this category will ever have. A field that treats the existence of a mechanism as the end of the argument tends to skip past exactly this kind of finding.
CJC-1295 (no DAC): an inferred receptor and an empty human file
The naming is the first thing to get right, because it determines what evidence applies. CJC-1295 proper was described as a tetrasubstituted human GRF(1–29) bearing a C-terminal maleimidopropionamide lysine — the albumin-reactive drug affinity complex, or DAC — which is the feature that defines the molecule (Jetté et al., 2005). “CJC-1295 (no DAC)”, also sold as modified GRF (1–29), is the same tetrasubstituted GHRH(1–29) analog without that complex. Removing the DAC removes the entire pharmacokinetic rationale of the parent compound.
Receptor action: inferred, and labelled as such
As a GHRH(1–29) analog it is expected to act on the GHRH receptor of pituitary somatotrophs. The qualification is important and comes from the record itself: this is inferred from related compounds rather than measured directly for this molecule. Compare that with ipamorelin, where the receptor assignment rests on the compound's own pharmacology. Two compounds described in the same catalogue sentence can sit at very different levels of evidential confidence about something as basic as which receptor they hit.
The half-life transfer error
The most common mistake in writing about this compound is importing the parent molecule's human data. The published CJC-1295 human study (Teichman et al., 2006) examined the DAC version, whose albumin binding is what extends its half-life. Those results do not transfer to the no-DAC form. The albumin conjugation story was the whole point of the DAC design — the originating work identified CJC-1295 specifically as a long-lasting GRF analog by virtue of the bioconjugate (Jetté et al., 2005). Strip the complex, and the citation that supported the long-acting claim no longer describes the molecule in the vial.
Where the evidence stops
A 2026 peer-reviewed review of performance-enhancing peptides modulating the GH–IGF1 axis found no peer-reviewed human studies of CJC-1295 without DAC and placed it in its lowest evidence tier (Dominikowski et al., 2026). The remaining published research areas are narrow: its status as a structural analog of GHRH(1–29), and doping-control detection work, including the identification of glycine-modified growth hormone secretagogues in seized material (Gajda et al., 2019). Analytical chemistry on seized samples is real science, but it is evidence about detection, not about pharmacology.
The combination vial
The catalogue also lists CJC-1295 + Ipamorelin, a single vial containing CJC-1295 (no DAC) and ipamorelin — one GHRH-receptor agonist and one ghrelin-receptor agonist. The listing states the position accurately: published research examines these compounds individually, not as this combination. The two-receptor rationale is often presented as if it were a finding; it is a hypothesis about complementary targets, and no study in the reviewed literature tests the pair. The same reasoning gap appears in multi-component vials elsewhere in the catalogue, which we work through in CS-GLW and CS-KLW blends compared.
Characterisation and handling
The analytical problem differs with chain length. A pentapeptide such as ipamorelin gives a simple RP-HPLC profile and an unambiguous mass confirmation. A 29-residue GHRH analog is a harder synthesis: the impurity profile includes deletion and truncation sequences that are chemically close to the target, so chromatographic resolution and mass-spectrometric confirmation carry more weight. For a no-DAC analog, mass confirmation is also the practical check that the albumin-binding complex is genuinely absent — the DAC and no-DAC forms differ in mass, and a certificate is where that question is settled rather than assumed. Each lot's certificate of analysis states the measured purity and identity for that lot.
| Field | Ipamorelin | CJC-1295 (no DAC) |
|---|---|---|
| Format | Lyophilised powder, glass vial, crimp seal, flip-top cap | Lyophilised powder, glass vial, crimp seal, flip-top cap |
| Sizes | 5 mg, 10 mg | 10 mg |
| House codes | CS-IPA-5, CS-IPA-10 | CS-CJC-10 |
| Storage | −20 °C, desiccated | −20 °C, desiccated |
| Lot documentation | RP-HPLC identity and measured purity, mass confirmation | RP-HPLC identity and measured purity, mass confirmation |
For a worked example of how a compound can have a fully resolved structure and a named receptor family while its mechanism remains explicitly unknown, see our PT-141 receptor pharmacology review; for the opposite pattern — a long in-vitro literature with a contested mechanism — see GHK-Cu research: what the studies actually show.
Frequently asked questions
What is the real difference between ipamorelin and CJC-1295 (no DAC)?
The receptor. Ipamorelin acts on the ghrelin receptor (GHS-R1a); the GHRH(1–29) analog is expected to act on the GHRH receptor, though for the no-DAC form that is inferred from related compounds rather than measured directly. They also differ in size — five residues against twenty-nine — and in how much human data exist.
Which of the two has more published evidence?
Ipamorelin, clearly. It has a human pharmacokinetic–pharmacodynamic study and a completed, published phase 2 controlled trial. A 2026 review found no peer-reviewed human studies of CJC-1295 without DAC and placed it in its lowest evidence tier.
Does the published CJC-1295 half-life apply to the no-DAC version?
No. The human CJC-1295 data concern the DAC version, whose albumin binding is what extends its half-life. Removing the complex removes the basis for that result, so those findings do not transfer.
Is there research on the two compounds combined?
Not in the reviewed literature. The combination vial's own listing states that published research examines the compounds individually, not as that combination.
See it in the catalogue: Ipamorelin.
For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.